Skip to main content
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
10.34
+0.18 (1.77%)
At close: Dec 5, 2025, 4:00 PM EST
10.32
-0.02 (-0.19%)
After-hours: Dec 5, 2025, 5:01 PM EST

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
370612503424534-
Upgrade
Market Cap Growth
-41.18%21.70%18.72%-20.71%--
Upgrade
Enterprise Value
96224219236610-
Upgrade
Last Close Price
10.3217.2915.0913.5217.12-
Upgrade
PE Ratio
-9.33----
Upgrade
PS Ratio
6.912.903.90---
Upgrade
PB Ratio
1.091.432.081.991.79-
Upgrade
P/TBV Ratio
1.091.432.081.991.79-
Upgrade
P/FCF Ratio
--3.75---
Upgrade
P/OCF Ratio
--3.60---
Upgrade
EV/Sales Ratio
1.551.061.69---
Upgrade
EV/EBITDA Ratio
-4.41----
Upgrade
EV/EBIT Ratio
-4.77----
Upgrade
EV/FCF Ratio
--1.63---
Upgrade
Debt / Equity Ratio
0.150.140.280.12--
Upgrade
Debt / EBITDA Ratio
-0.924.68---
Upgrade
Debt / FCF Ratio
--0.51---
Upgrade
Asset Turnover
0.130.420.36---
Upgrade
Quick Ratio
13.7410.782.268.6243.3211.62
Upgrade
Current Ratio
14.0811.152.339.5544.4611.89
Upgrade
Return on Equity (ROE)
-27.11%19.56%-2.94%-37.01%-30.19%-93.94%
Upgrade
Return on Assets (ROA)
-15.71%5.90%-0.55%-21.79%-18.29%-53.97%
Upgrade
Return on Capital (ROIC)
-17.33%7.36%-0.72%-22.63%-18.86%-59.03%
Upgrade
Return on Capital Employed (ROCE)
-31.30%9.70%-1.00%-42.30%-17.10%-66.40%
Upgrade
Earnings Yield
-27.95%10.72%-1.33%-22.33%-9.57%-
Upgrade
FCF Yield
-35.07%-7.30%26.68%-22.82%-10.38%-
Upgrade
Buyback Yield / Dilution
-15.95%-18.01%-5.62%-399.27%-467.09%-18.45%
Upgrade
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q